EdiGene is a biotechnology company using genetic editing technologies to develop therapies for the treatment of cancer and genetic diseases that is headquartered in Tokyo, Japan and was founded in 2015 by Haru Morita and Osamu Nureki. The company is using its proprietary CRISPR and protein engineering platforms with technologies licensed intellectual property from the University of Tokyo.
On February 4, 2019 EdiGene completed their series pre-B funding round with $10 million in funding from Green Pine Capital Partners (lead investor), IDG Capital, Lilly Asia Ventures, and other undisclosed investors. The founder of EdiGene, Wensheng Wei, made the following comments to reporters regarding the companies series pre-B funding round:
We are pleased to complete this new round of financing led by Green Pine with participation of existing investors. As we are advancing our sciences, we look forward to working with Green Pine and our current investors to grow EdiGene into the next exciting phase.
On April 10, 2019 EdiGene completed their series B funding round with $15 million in funding from UTokyo Innovation Platform, SBI Investment, Fast Track Initiative, SMBC Venture Capital, Mizuho Capital, CareNet Group. The CEO of Edigene, Haru Morita, made the following comments to reporters regarding the companies successful series B funding round:
Since the founding of EdiGENE in 2016, we have made remarkable progress in developing CRISPR-GNDM as a new therapeutic modality for precision gene therapy. We are excited to have the support from this group of investors to help us achieve our mission.
On May 24, 2019 EdiGene expanded their series B funding round with $8 million in funding from Shinsei Capital Partners and Pegasus Tech Ventures. The company claims the additional funding will be used for expanding the companies operations and help expand into new therapeutic areas.